Intrastromal injection of bevacizumab in patients with corneal neovascularization
Corneal neovascularization (NV) not only reduces visual acuity, but it also causes loss of the cornea's immune privilege, strongly contributing to a worse prognosis in penetrating keratoplasty. Several mediators participate in corneal angiogenesis, and the role of vascular endothelial growth factor (VEGF) has been extensively proven. Anti-VEGF agents have been shown to be effective in slowing the growth of corneal neovessels. Bevacizumab, an anti-VEGF agent, has been successfully used in the treatment of corneal neovascularization. In this paper, we report a series of patients who underwent intracorneal bevacizumab injections to treat corneal vascularization.
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Conselho Brasileiro de Oftalmologia
2012
|
| Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492012000400012 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|